These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38293058)

  • 21. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
    Lannfelt L
    Ups J Med Sci; 2023; 128():. PubMed ID: 38084203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.
    Johannesson M; Sahlin C; Söderberg L; Basun H; Fälting J; Möller C; Zachrisson O; Sunnemark D; Svensson A; Odergren T; Lannfelt L
    Mol Cell Neurosci; 2021 Jul; 114():103641. PubMed ID: 34091073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Aruffo E; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):863-881. PubMed ID: 37009976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [
    Liang C; Paclibar CG; Gonzaga NL; Sison SA; Bath HS; Biju AP; Mukherjee J
    Neurol Int; 2024 Apr; 16(2):419-431. PubMed ID: 38668128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
    Honig LS; Barakos J; Dhadda S; Kanekiyo M; Reyderman L; Irizarry M; Kramer LD; Swanson CJ; Sabbagh M
    Alzheimers Dement (N Y); 2023; 9(1):e12377. PubMed ID: 36949897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
    Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
    Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.
    Loeffler DA
    J Alzheimers Dis Rep; 2023; 7(1):873-899. PubMed ID: 37662616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advancements and Challenges in Antiamyloid Therapy for Alzheimer's Disease: A Comprehensive Review.
    Beshir SA; Hussain N; Menon VB; Al Haddad AHI; Al Zeer RAK; Elnour AA
    Int J Alzheimers Dis; 2024; 2024():2052142. PubMed ID: 39081336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy.
    Singh PK; Berk-Rauch HE; Soplop N; Uryu K; Strickland S; Ahn HJ
    J Vis Exp; 2018 Nov; (141):. PubMed ID: 30582601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems.
    Loeffler DA
    J Alzheimers Dis; 2024; 100(2):379-411. PubMed ID: 38875041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.
    Cortes-Canteli M; Paul J; Norris EH; Bronstein R; Ahn HJ; Zamolodchikov D; Bhuvanendran S; Fenz KM; Strickland S
    Neuron; 2010 Jun; 66(5):695-709. PubMed ID: 20547128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lecanemab: Appropriate Use Recommendations.
    Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
    J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How will the emergence of lecanemab change dementia treatment?
    Iwata A
    Geriatr Gerontol Int; 2024 Sep; 24(9):841-844. PubMed ID: 39034660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review.
    Hossain MF; Husna AU; Kharel M
    Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.
    Singh PK; Kawasaki M; Berk-Rauch HE; Nishida G; Yamasaki T; Foley MA; Norris EH; Strickland S; Aso K; Ahn HJ
    Biochemistry; 2018 Feb; 57(8):1399-1409. PubMed ID: 29394041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains.
    Stern AM; Yang Y; Jin S; Yamashita K; Meunier AL; Liu W; Cai Y; Ericsson M; Liu L; Goedert M; Scheres SHW; Selkoe DJ
    Neuron; 2023 Jul; 111(13):2012-2020.e4. PubMed ID: 37167969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer's Disease Therapy.
    Bellier JP; Roman A; Christiano C; Anzai JA; Moreno S; Campbell EC; Godwin L; Li A; Chen A; Alan SM; Saba A; Yoo HB; Yang HS; Chhatwal JP; Selkoe DJ; Liu L
    bioRxiv; 2024 May; ():. PubMed ID: 38746192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody.
    Noguchi-Shinohara M; Ono K
    Intern Med; 2024 Oct; ():. PubMed ID: 39401909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.